Kil et al. reported that silibinin (50 μg/mL) could inhibit metastasis and migration by inhibiting EGFR phosphorylation and suppressing VEGF, MMP‐9, and COX‐2 in MDA‐MB‐468 cells, resulting in decreased tumor volume in the triple‐negative BC xenograft model.136. Here, EGFR is linked to breast cancer.